1. Engineered Tumor-Targeted T Cells Mediate Enhanced Anti-Tumor Efficacy Both Directly and through Activation of the Endogenous Immune System
- Author
-
Avanzi, Mauro P, Yeku, Oladapo, Li, Xinghuo, Wijewarnasuriya, Dinali P, van Leeuwen, Dayenne G, Cheung, Kenneth, Park, Hyebin, Purdon, Terence J, Daniyan, Anthony F, Spitzer, Matthew H, and Brentjens, Renier J
- Subjects
Biological Sciences ,Lymphoma ,Pediatric Cancer ,Vaccine Related ,Pediatric ,Rare Diseases ,Immunization ,Gene Therapy ,Cancer ,Hematology ,Genetics ,Biotechnology ,5.2 Cellular and gene therapies ,Development of treatments and therapeutic interventions ,5.1 Pharmaceuticals ,Animals ,Antineoplastic Agents ,Autocrine Communication ,B-Lymphocytes ,Cell Proliferation ,Cell Survival ,Disease Models ,Animal ,Humans ,Immune System ,Immunotherapy ,Immunotherapy ,Adoptive ,Interleukin-18 ,Mice ,Inbred C57BL ,Mice ,SCID ,Neoplasms ,Signal Transduction ,T-Lymphocytes ,Tumor Microenvironment ,Xenograft Model Antitumor Assays ,B-ALL ,CAR T cell ,IL-18 ,MUC16 ,adoptive transfer ,armored CAR ,chimeric antigen receptor ,interleukin-18 ,ovarian cancer ,Biochemistry and Cell Biology ,Medical Physiology ,Biological sciences - Abstract
Chimeric antigen receptor (CAR) T cell therapy has proven clinically beneficial against B cell acute lymphoblastic leukemia and non-Hodgkin's lymphoma. However, suboptimal clinical outcomes have been associated with decreased expansion and persistence of adoptively transferred CAR T cells, antigen-negative relapses, and impairment by an immunosuppressive tumor microenvironment. Improvements in CAR T cell design are required to enhance clinical efficacy, as well as broaden the applicability of this technology. Here, we demonstrate that interleukin-18 (IL-18)-secreting CAR T cells exhibit enhanced in vivo expansion and persistence and significantly increase long-term survival in syngeneic mouse models of both hematological and solid malignancies. In addition, we demonstrate that IL-18-secreting CAR T cells are capable of modulating the tumor microenvironment, as well as enhancing an effective endogenous anti-tumor immune response. IL-18-secreting CAR T cells represent a promising strategy to enhance the clinical outcomes of adoptive T cell therapy.
- Published
- 2018